FDA approves Genzyme pediatric leukemia drug

12/30/2004 | Wall Street Journal, The

The FDA approved Genzyme's leukemia drug, Clolar, assigning orphan status to the drug developed for treating patients age 21 and younger who do not respond to chemotherapy. Genzyme expects the drug to be available in January, at an estimated price of $34,000 per dose. One expert said it is likely the drug also will be used off-label in combination with other treatments for adult patients.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA